NCT06992739 2026-04-14
PROTECT-2
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
Clinical Trials
6 trialsNCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06328049 2024-03-25
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
Taixing People's Hospital
Phase 2 Unknown
NCT06297811 2024-03-07
Myeloprotection With Trilaciclib in Pan-cancer Population
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05900921 2023-06-13
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
Sichuan University
Phase 2 Unknown